Physician profile
Blesson John
NPI 1871190439
$2,841.47
in general payments reported to CMS, 2019-2025
19 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $453 · 2023: $60.84 · 2024: $1,450 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406 · Travel and Lodging: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.15 |
| Travel and Lodging | $563.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $957.57 | 2024 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $338.69 | 2024-2025 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $218.26 | 2021 | |
| Boston Scientific Corporation | $203.68 | 2023-2025 | Intracept Rf Probe, Intracept, Click |
| Si-Bone, INC. | $199.72 | 2024 | |
| Depuy Synthes Sales INC. | $129.60 | 2022 | |
| Melinta Therapeutics, LLC | $124.98 | 2021 | |
| Medical Device Business Services, INC. | $115.14 | 2022 | |
| Smith+Nephew, INC. | $97.43 | 2022 | |
| Heron Therapeutics, INC. | $86.40 | 2022 | |
| Amgen INC. | $75.67 | 2021 | |
| Davol INC. | $71.64 | 2022-2024 | Arista Ah Flexitip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.71 | 2024-2025 | Relistor |
| Abbvie INC. | $49.99 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $23.43 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $20.88 | 2025 | Hymovis, Triluron |
| Collegium Pharmaceutical, INC. | $20.82 | 2024 | Belbuca |
| Kci USA, INC. | $19.16 | 2023 | V.A.C. Veraflo, V.A.C. Dermatac |
| Averitas Pharma INC. | $18.70 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blesson John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.